Table of Contents

Research Articles: Therapeutics, Targets, and Development

• Research Articles: Therapeutics, Targets, and Development

  Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-κB, p53, bax, and p27 levels

  Catherine A. Tucker, Anita I. Kapanen, Ghania Chikh, Brad G. Hoffman, Alastair H. Kyle, Ian M. Wilson, Dana Masin, Randy D. Gascoyne, Marcel Bally and Richard J. Klasa

  Mol Cancer Ther April 1 2008 7 (4) 749-758; DOI:10.1158/1535-7163.MCT-07-0302

  
  
• Research Articles: Therapeutics, Targets, and Development

  MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

  Marielle Fournel, Claire Bonfils, Yu Hou, Pu Theresa Yan, Marie-Claude Trachy-Bourget, Ann Kalita, Jianhong Liu, Ai-Hua Lu, Nancy Z. Zhou, Marie-France Robert, Jeffrey Gillespie, James J. Wang, Hélène Ste-Croix, Jubrail Rahil, Sylvain Lefebvre, Oscar Moradei, Daniel Delorme, A. Robert MacLeod, Jeffrey M. Besterman and Zuomei Li

  Mol Cancer Ther April 1 2008 7 (4) 759-768; DOI:10.1158/1535-7163.MCT-07-2026

  
  
• Research Articles: Therapeutics, Targets, and Development

  Small molecules targeting histone H4 as potential therapeutics for chronic myelogenous leukemia

  C. James Chou, Michelle E. Farkas, Sherry M. Tsai, David Alvarez, Peter B. Dervan and Joel M. Gottesfeld

  Mol Cancer Ther April 1 2008 7 (4) 769-778; DOI:10.1158/1535-7163.MCT-08-0130

  
  
• Research Articles: Therapeutics, Targets, and Development

  Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models

  Yasushi Sasaki, Hideaki Negishi, Masashi Idogawa, Hiromu Suzuki, Hiroaki Mita, Minoru Toyota, Yasuhisa Shinomura, Kohzoh Imai and Takashi Tokino

  Mol Cancer Ther April 1 2008 7 (4) 779-787; DOI:10.1158/1535-7163.MCT-07-0395

  
  
• Research Articles: Therapeutics, Targets, and Development

  Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma

  Nathan R. Miselis, Zhijin J. Wu, Nico Van Rooijen and Agnes B. Kane

  Mol Cancer Ther April 1 2008 7 (4) 788-799; DOI:10.1158/1535-7163.MCT-07-0579

  
  
• Research Articles: Therapeutics, Targets, and Development

  Sensitizing estrogen receptor–negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor

  Shu-Chuan Weng, Yoko Kashida, Samuel K. Kulp, Dasheng Wang, Robert W. Brueggemeier, Charles L. Shapiro and Ching-Shih Chen

  Mol Cancer Ther April 1 2008 7 (4) 800-808; DOI:10.1158/1535-7163.MCT-07-0434

  
  
• Research Articles: Therapeutics, Targets, and Development

  2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition

  Diansheng Zhong, Xiuju Liu, Katherine Schafer-Hales, Adam I. Marcus, Fadlo R. Khuri, Shi-Yong Sun and Wei Zhou

  Mol Cancer Ther April 1 2008 7 (4) 809-817; DOI:10.1158/1535-7163.MCT-07-0559

  
  
• Research Articles: Therapeutics, Targets, and Development

  Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy

  Cathy Zhang, Karen Lundgren, Zhengming Yan, Maria E. Arango, Sharon Price, Andrea Huber, Joseph Higgins, Gabriel Troche, Judith Skaptason, Tatiana Koudriakova, Jim Nonomiya, Michelle Yang, Patrick O'Connor, Steve Bender, Gerrit Los, Cristina Lewis and Bart Jessen

  Mol Cancer Ther April 1 2008 7 (4) 818-828; DOI:10.1158/1535-7163.MCT-07-0440

  
  
• Research Articles: Therapeutics, Targets, and Development

  LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis

  Davide Melisi, Satoshi Ishiyama, Guido M. Sclabas, Jason B. Fleming, Qianghua Xia, Giampaolo Tortora, James L. Abbruzzese and Paul J. Chiao

  Mol Cancer Ther April 1 2008 7 (4) 829-840; DOI:10.1158/1535-7163.MCT-07-0337

  
  
• Research Articles: Therapeutics, Targets, and Development

  Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma

  Jack S. Chen, Linda J. Zhou, Michal Entin-Meer, Xiaodong Yang, Mila Donker, Zachary A. Knight, William Weiss, Kevan M. Shokat, Daphne Haas-Kogan and David Stokoe

  Mol Cancer Ther April 1 2008 7 (4) 841-850; DOI:10.1158/1535-7163.MCT-07-0393

  
  
• Research Articles: Therapeutics, Targets, and Development

  Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature

  Lin Cao, Pan Du, Shu-Han Jiang, Guang-Hui Jin, Qi-Lai Huang and Zi-Chun Hua

  Mol Cancer Ther April 1 2008 7 (4) 851-861; DOI:10.1158/1535-7163.MCT-07-0533

  
  
• Research Articles: Therapeutics, Targets, and Development

  Antitumor activity of fibroblast growth factor receptor 3–specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis

  Jorge L. Martínez-Torrecuadrada, Lawrence H. Cheung, Paula López-Serra, Rodrigo Barderas, Marta Cañamero, Sergio Ferreiro, Michael G. Rosenblum and J. Ignacio Casal

  Mol Cancer Ther April 1 2008 7 (4) 862-873; DOI:10.1158/1535-7163.MCT-07-0394

  
  
• Research Articles: Therapeutics, Targets, and Development

  The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor

  Nadia Godin-Heymann, Lindsey Ulkus, Brian W. Brannigan, Ultan McDermott, Jennifer Lamb, Shyamala Maheswaran, Jeffrey Settleman and Daniel A. Haber

  Mol Cancer Ther April 1 2008 7 (4) 874-879; DOI:10.1158/1535-7163.MCT-07-2387

  
  
• Research Articles: Therapeutics, Targets, and Development

  The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex–interactive agents

  Daekyu Sun, Wei-Jun Liu, Kexiao Guo, Jadrian J. Rusche, Scot Ebbinghaus, Vijay Gokhale and Laurence H. Hurley

  Mol Cancer Ther April 1 2008 7 (4) 880-889; DOI:10.1158/1535-7163.MCT-07-2119

  
  
• Research Articles: Therapeutics, Targets, and Development

  Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells

  Grazia Ambrosini, Haider S. Cheema, Sharon Seelman, Allison Teed, Elliot B. Sambol, Samuel Singer and Gary K. Schwartz

  Mol Cancer Ther April 1 2008 7 (4) 890-896; DOI:10.1158/1535-7163.MCT-07-0518

  
  
• Research Articles: Therapeutics, Targets, and Development

  Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells

  Deepika Dhawan, Antonella Borgatti Jeffreys, Rong Zheng, Jane C. Stewart and Deborah W. Knapp

  Mol Cancer Ther April 1 2008 7 (4) 897-904; DOI:10.1158/1535-7163.MCT-07-0313

  
  
• Research Articles: Therapeutics, Targets, and Development

  UBE1L represses PML/RARα by targeting the PML domain for ISG15ylation

  Sumit J. Shah, Steven Blumen, Ian Pitha-Rowe, Sutisak Kitareewan, Sarah J. Freemantle, Qing Feng and Ethan Dmitrovsky

  Mol Cancer Ther April 1 2008 7 (4) 905-914; DOI:10.1158/1535-7163.MCT-07-0515

  
  
• Research Articles: Therapeutics, Targets, and Development

  Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells

  Maria Serova, Aïda Ghoul, Karim A. Benhadji, Sandrine Faivre, Christophe Le Tourneau, Esteban Cvitkovic, Francois Lokiec, Janet Lord, Steven M. Ogbourne, Fabien Calvo and Eric Raymond

  Mol Cancer Ther April 1 2008 7 (4) 915-922; DOI:10.1158/1535-7163.MCT-07-2060

  
  
• Research Articles: Therapeutics, Targets, and Development

  SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome

  Xuefei Cao, Carlos Clavijo, Xu Li, H. Helen Lin, Yuan Chen, Hsiu-Ming Shih and David K. Ann

  Mol Cancer Ther April 1 2008 7 (4) 923-934; DOI:10.1158/1535-7163.MCT-07-0540

  
  
• Research Articles: Therapeutics, Targets, and Development

  Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines

  Joel Greshock, Jie Cheng, David Rusnak, Anne Marie Martin, Richard Wooster, Tona Gilmer, Kwan Lee, Barbara L. Weber and Tal Zaks

  Mol Cancer Ther April 1 2008 7 (4) 935-943; DOI:10.1158/1535-7163.MCT-07-2072

  
  
• Research Articles: Therapeutics, Targets, and Development

  Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy

  Judith A. Gilbert, Matthew P. Goetz, Carol A. Reynolds, James N. Ingle, Karin F. Giordano, Vera J. Suman, Hilary E. Blair, Robert B. Jenkins, Wilma L. Lingle, Monica M. Reinholz, Alex A. Adjei and Matthew M. Ames

  Mol Cancer Ther April 1 2008 7 (4) 944-951; DOI:10.1158/1535-7163.MCT-07-0570

  
  
• Research Articles: Therapeutics, Targets, and Development

  A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras

  Yanan Yang, Marie Wislez, Nobukazu Fujimoto, Ludmila Prudkin, Julie G. Izzo, Futoshi Uno, Lin Ji, Amy E. Hanna, Robert R. Langley, Diane Liu, Faye M. Johnson, Ignacio Wistuba and Jonathan M. Kurie

  Mol Cancer Ther April 1 2008 7 (4) 952-960; DOI:10.1158/1535-7163.MCT-07-2045

  
  
• Research Articles: Therapeutics, Targets, and Development

  Vitamin E succinate induces NAG-1 expression in a p38 kinase-dependent mechanism

  Minsub Shim and Thomas E. Eling

  Mol Cancer Ther April 1 2008 7 (4) 961-971; DOI:10.1158/1535-7163.MCT-07-0470

  
  
• Research Articles: Therapeutics, Targets, and Development

  Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes

  Ronald A. Lubet, Eva Szabo, Konstantin Christov, Ann M. Bode, Marna E. Ericson, Vernon E. Steele, M. Margaret Juliana and Clinton J. Grubbs

  Mol Cancer Ther April 1 2008 7 (4) 972-979; DOI:10.1158/1535-7163.MCT-07-2141

  
  
• Research Articles: Therapeutics, Targets, and Development

  WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells

  Andrew R. Cuddihy, Farid Jalali, Carla Coackley and Robert G. Bristow

  Mol Cancer Ther April 1 2008 7 (4) 980-992; DOI:10.1158/1535-7163.MCT-07-0471

  
  
• Research Articles: Therapeutics, Targets, and Development

  Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53

  Stéphane Supiot, Richard P. Hill and Robert G. Bristow

  Mol Cancer Ther April 1 2008 7 (4) 993-999; DOI:10.1158/1535-7163.MCT-07-0442